- Home
- PETS vs RFL Comparison
PETS vs RFL Comparison
Compare PETS & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PETS | RFL |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Real Estate |
| Sector | Consumer Staples | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.8M | 54.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PETS | RFL |
|---|---|---|
| Price | $1.65 | $1.23 |
| Analyst Decision | Sell | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.20 | N/A |
| AVG Volume (30 Days) | ★ 214.6K | 91.1K |
| Earning Date | 02-02-2026 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $226,972,000.00 | $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $1.59 | $1.17 |
| 52 Week High | $6.85 | $3.19 |
Technical Indicators
Market Signals| Indicator | PETS | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 32.70 | 43.20 |
| Support Level | $1.69 | $1.20 |
| Resistance Level | $1.83 | $1.29 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 13.04 | 50.00 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.